At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 251 enrolled
Drug / intervention
bimagrumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
In Brief
A Phase 2 clinical trial evaluating bimagrumab and placebo for Muscle Wasting (Atrophy) After Hip Fracture Surgery. Completed, enrolled 251 participants across 53 sites in 19 countries.
Detailed Summary
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Austria, Belgium, Chile, Colombia, Czechia, France, Germany, Hungary, Japan, Mexico, Russia, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartSep 2014
Primary CompletionMay 2018
Study CompletionOct 2018
TodayJul 2026
First PostedJun 2, 2014
Enrollment StartSep 16, 2014
Primary CompletionMay 14, 2018
Study CompletionOct 25, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.1 years ago
Interventions
bimagrumabdrug
Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
placeboother
Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.